As IRS-1 and IRS-2 are thought to mediate most of the effects of IR and IGF-1R in breast cancer cells, it may be possible to disrupt this molecule without affecting normal glucose homeostasis mediated by other adapter proteins in insulin target organs. The gene discussed is IRS2; the disease is breast cancer.